Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...

Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

Four of the 10 medications Statista anticipates will yield the largest sales in 2026 are GLP-1 medications, according to data shared with Becker’s. Compared to last year’s predictions, Eli ...

Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal on Wednesday.

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

Unlike Keytruda and Ozempic, there are no clear headwinds in Biktarvy ... Regeneron, for instance, has been trying to get its high-dose Eylea brand off the ground with limited success so far. In the ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on ...